Transitional cell carcinoma pathophysiology: Difference between revisions
Mahshid |
|||
Line 1: | Line 1: | ||
<div style="-webkit-user-select: none;"> | <div style="-webkit-user-select: none;"> | ||
{|class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right; | {| class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;" | ||
|- | |- | ||
| {{#ev:youtube|https://https://www.youtube.com/watch?v=zv-vOLDOcRE|350}} | | {{#ev:youtube|https://https://www.youtube.com/watch?v=zv-vOLDOcRE|350}} | ||
Line 12: | Line 12: | ||
==Pathogenesis== | ==Pathogenesis== | ||
*The surface epithelium (urothelium) that lines the mucosal surfaces of the entire urinary tract is exposed to potential carcinogens that are either excreted in the urine or activated from precursors in the urine by hydrolyzing enzymes. | |||
*This "field cancerization" effect is one hypothesis to explain the multifocal occurrence that is a characteristic feature of urothelial carcinomas of both the urinary bladder and the upper urinary tract.<ref name="pmid11134200">{{cite journal |vauthors=Rabbani F, Perrotti M, Russo P, Herr HW |title=Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance |journal=J. Clin. Oncol. |volume=19 |issue=1 |pages=94–100 |date=January 2001 |pmid=11134200 |doi=10.1200/JCO.2001.19.1.94 |url=}}</ref> | |||
*In the majority of cases, multifocal urothelial carcinomas are monoclonal which supports their presumed origin from a single genetically altered cell,referred to as the monoclonality hypothesis. | |||
*Under normal conditions, the [[bladder]], the lower part of the [[kidneys]], the [[ureters]], and the proximal [[urethra]] are lined with a specialized mucous membrane referred to as transitional epithelium (also called [[urothelium]]). | *Under normal conditions, the [[bladder]], the lower part of the [[kidneys]], the [[ureters]], and the proximal [[urethra]] are lined with a specialized mucous membrane referred to as transitional epithelium (also called [[urothelium]]). | ||
*Most [[cancers]] that form in the bladder, the lower part of the kidneys, the ureters, and the proximal urethra are transitional cell carcinomas (also called urothelial carcinomas) that derive from transitional epithelium. | *Most [[cancers]] that form in the bladder, the lower part of the kidneys, the ureters, and the proximal urethra are transitional cell carcinomas (also called urothelial carcinomas) that derive from transitional epithelium. | ||
===Genetics=== | ===Genetics=== | ||
* Genetic [[mutations]] involved in the pathogenesis of bladder cancer include:<ref name=”cancergov”>National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq#link/_359_toc Accessed on February 19, 2016</ref> | * Genetic [[mutations]] involved in the pathogenesis of bladder cancer include:<ref name="”cancergov”">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq#link/_359_toc Accessed on February 19, 2016</ref> | ||
:* [[HRAS]] mutation | :* [[HRAS]] mutation | ||
:* [[Retinoblastoma protein|Rb1]] mutation | :* [[Retinoblastoma protein|Rb1]] mutation | ||
Line 27: | Line 30: | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Type'''}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Type'''}} | ||
Line 34: | Line 37: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Non-invasive urothelial carcinoma | Non-invasive urothelial carcinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Flat [[lesions]] or papillary lesions | *Flat [[lesions]] or papillary lesions | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Invasive urothelial carcinoma | Invasive urothelial carcinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Large infiltrative [[mass]] or a multifocal, flat to papillary lesion with delicate fronds | *Large infiltrative [[mass]] or a multifocal, flat to papillary lesion with delicate fronds | ||
|} | |} | ||
Line 57: | Line 60: | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Subtype'''}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Subtype'''}} | ||
Line 64: | Line 67: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Urothelial carcinomas with squamous differentiation | Urothelial carcinomas with squamous differentiation | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Presence of urothelial and [[Squamous cell|squamous cells]] | *Presence of urothelial and [[Squamous cell|squamous cells]] | ||
*Observed in 44% of renal pelvis tumors | *Observed in 44% of renal pelvis tumors | ||
Line 70: | Line 73: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Urothelial carcinomas with glandular differentiation | Urothelial carcinomas with glandular differentiation | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Presence of gland cells and true glandular spaces | *Presence of gland cells and true glandular spaces | ||
*[[Mucin]] production | *[[Mucin]] production | ||
Line 77: | Line 80: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Micropapillary urothelial carcinomas | Micropapillary urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Presence of micropapillae | *Presence of micropapillae | ||
*High grade [[neoplasm]] | *High grade [[neoplasm]] | ||
Line 83: | Line 86: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Sarcomatoid urothelial carcinomas | Sarcomatoid urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Presence of cells that look like sarcoma | *Presence of cells that look like sarcoma | ||
*This aggressive carcinoma has often spread to [[lymph nodes]] and organs other than the renal pelvis or ureter when it is diagnosed | *This aggressive carcinoma has often spread to [[lymph nodes]] and organs other than the renal pelvis or ureter when it is diagnosed | ||
Line 89: | Line 92: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Nested variant of urothelial carcinomas | Nested variant of urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Irregular and confluent small nests and abortive tubules are composed of urothelial cells | *Irregular and confluent small nests and abortive tubules are composed of urothelial cells | ||
*Very rare but aggressive | *Very rare but aggressive | ||
Line 95: | Line 98: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Microcystic urothelial carcinomas | Microcystic urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Cysts in them that can range in size from microscopic to 2 mm | *Cysts in them that can range in size from microscopic to 2 mm | ||
*Very rare | *Very rare | ||
Line 101: | Line 104: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Lymphoepithelioma-like urothelial carcinomas | Lymphoepithelioma-like urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Lymphatic tissue mixed with urothelial cells, or transitional cells | *Lymphatic tissue mixed with urothelial cells, or transitional cells | ||
*Very rare carcinoma | *Very rare carcinoma | ||
Line 108: | Line 111: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Plasmacytoid and lymphoma-like urothelial carcinomas | Plasmacytoid and lymphoma-like urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Tumor cells that look like [[lymphoma]] or [[plasmacytoma]] | *Tumor cells that look like [[lymphoma]] or [[plasmacytoma]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
[[Giant cell]] urothelial carcinomas | [[Giant cell]] urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Abnormally large cells with more than one [[nucleus]] | *Abnormally large cells with more than one [[nucleus]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Clear cell urothelial carcinomas | Clear cell urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*[[Clear cell|Clear cells]] (cells with clear cytoplasm and a large nucleus) | *[[Clear cell|Clear cells]] (cells with clear cytoplasm and a large nucleus) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Lipid cell variant of urothelial carcinomas | Lipid cell variant of urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Cells that are filled with fat | *Cells that are filled with fat | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Undifferentiated variant of urothelial carcinomas | Undifferentiated variant of urothelial carcinomas | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Cells that don’t have any clear features and don’t look like any other type of cell (they are undifferentiated). | *Cells that don’t have any clear features and don’t look like any other type of cell (they are undifferentiated). | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Urothelial carcinomas with trophoblastic differentiation | Urothelial carcinomas with trophoblastic differentiation | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Presence of cells that look like [[Trophoblast|trophoblasts]] | *Presence of cells that look like [[Trophoblast|trophoblasts]] | ||
*[[Human chorionic gonadotropin]] production within the cells | *[[Human chorionic gonadotropin]] production within the cells | ||
Line 141: | Line 144: | ||
According to the WHO grading criteria, there are two grades of transitional cell carcinoma based on the degree of cellular differentiation: | According to the WHO grading criteria, there are two grades of transitional cell carcinoma based on the degree of cellular differentiation: | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Grade'''}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Grade'''}} | ||
Line 148: | Line 151: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Low grade | Low grade | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Tumors with the least degree of cellular anaplasia | *Tumors with the least degree of cellular anaplasia | ||
*Rarely invades the muscular wall of the bladder or spreads to other parts of the body | *Rarely invades the muscular wall of the bladder or spreads to other parts of the body | ||
Line 155: | Line 158: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
High grade | High grade | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
*Tumors with the most severe degrees of cellular anaplasia | *Tumors with the most severe degrees of cellular anaplasia | ||
*Commonly recurs and also has a | *Commonly recurs and also has a st [[Category:Disease]] [[Category:Up-To-Date]] [[Category:Oncology]] [[Category:Medicine]] rong tendency to invade the muscular wall of the bladder and spread to other parts of the body. | ||
*High grade transitional cell carcinoma is much more likely to result in death | *High grade transitional cell carcinoma is much more likely to result in death | ||
|} | |} | ||
Line 164: | Line 167: | ||
Following table illustrates the cancers that may be associated with transitional cell carcinoma of urinary tract:<ref name="KirkaliTuzel2003">{{cite journal|last1=Kirkali|first1=Ziya|last2=Tuzel|first2=Emre|title=Transitional cell carcinoma of the ureter and renal pelvis|journal=Critical Reviews in Oncology/Hematology|volume=47|issue=2|year=2003|pages=155–169|issn=10408428|doi=10.1016/S1040-8428(03)00079-9}}</ref> | Following table illustrates the cancers that may be associated with transitional cell carcinoma of urinary tract:<ref name="KirkaliTuzel2003">{{cite journal|last1=Kirkali|first1=Ziya|last2=Tuzel|first2=Emre|title=Transitional cell carcinoma of the ureter and renal pelvis|journal=Critical Reviews in Oncology/Hematology|volume=47|issue=2|year=2003|pages=155–169|issn=10408428|doi=10.1016/S1040-8428(03)00079-9}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | {| style="border: 0px; font-size: 90%; margin: 3px; width: 800px" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Association'''}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Association'''}} | ||
Line 171: | Line 174: | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Bladder cancer after the diagnosis of upper urinary tract transitional cell cancer | Bladder cancer after the diagnosis of upper urinary tract transitional cell cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
20 - 50% | 20 - 50% | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Upper urinary tract transitional cell cancer after the diagnosis of bladder cancer | Upper urinary tract transitional cell cancer after the diagnosis of bladder cancer | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
0.74 - 4% | 0.74 - 4% | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; align=left" | | ||
Upper urinary tract transitional cell cancer after cystectomy | Upper urinary tract transitional cell cancer after cystectomy | ||
| style="padding: 5px 5px; background: #F5F5F5;" align=left | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
2 - 9% | 2 - 9% | ||
|} | |} | ||
Line 190: | Line 193: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:21, 18 June 2019
https://https://www.youtube.com/watch?v=zv-vOLDOcRE%7C350}} |
Transitional cell carcinoma Microchapters |
Differentiating Transitional cell carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Transitional cell carcinoma pathophysiology On the Web |
American Roentgen Ray Society Images of Transitional cell carcinoma pathophysiology |
Directions to Hospitals Treating Transitional cell carcinoma |
Risk calculators and risk factors for Transitional cell carcinoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]
Overview
Genes involved in the pathogenesis of transitional cell carcinoma of bladder include HRAS, Rb1, PTEN/MMAC1, NAT2, and GSTM1. On gross pathology, flat lesions or papillary lesions are characteristic findings of non-invasive transitional cell carcinomas; a large infiltrative mass or a multifocal, flat to papillary lesion with delicate fronds are characteristic findings of invasive transitional cell carcinomas. On microscopic histopathological analysis, loss of cell polarity, nuclear crowding, and cytologic atypia are characteristic findings of flat lesion; fibrovascular stalks, umbrella cells, and eosinophilic cytoplasm are characteristic findings of papillary lesion; invasion beyond the basement membrane is the characteristic finding of invasive transitional cell carcinomas.
Pathogenesis
- The surface epithelium (urothelium) that lines the mucosal surfaces of the entire urinary tract is exposed to potential carcinogens that are either excreted in the urine or activated from precursors in the urine by hydrolyzing enzymes.
- This "field cancerization" effect is one hypothesis to explain the multifocal occurrence that is a characteristic feature of urothelial carcinomas of both the urinary bladder and the upper urinary tract.[1]
- In the majority of cases, multifocal urothelial carcinomas are monoclonal which supports their presumed origin from a single genetically altered cell,referred to as the monoclonality hypothesis.
- Under normal conditions, the bladder, the lower part of the kidneys, the ureters, and the proximal urethra are lined with a specialized mucous membrane referred to as transitional epithelium (also called urothelium).
- Most cancers that form in the bladder, the lower part of the kidneys, the ureters, and the proximal urethra are transitional cell carcinomas (also called urothelial carcinomas) that derive from transitional epithelium.
Genetics
Pathology
Gross Pathology
The following table illustrates the findings on gross pathology for the subtypes of transitional cell carcinoma:[3][4][5]
Type | Description |
---|---|
Non-invasive urothelial carcinoma |
|
Invasive urothelial carcinoma |
|
Microscopic Pathology
Non-invasive urothelial carcinoma
-
- Papillary lesions
- On microscopic histopathological analysis, fibrovascular stalks, umbrella cells, and eosinophilic cytoplasm are characteristic findings.
Invasive urothelial carcinoma
- Invasive urothelial carcinomas grow from the lining of the renal pelvis or ureter into the deeper layers of the renal pelvis or ureter wall, such as lamina propria and muscularis.[5]
- Transitional cell carcinomas with mixed epithelial features are invasive tumors that have different types of cells mixed with the cancer cells.
- They occur less often than typical invasive transitional cell carcinomas and are generally considered to be more aggressive.
- The following table illustrates the findings on microscopic analysis for invasive transitional cell carcinomas with mixed epithelial features:
Subtype | Features on Histopathological Microscopic Analysis |
---|---|
Urothelial carcinomas with squamous differentiation |
|
Urothelial carcinomas with glandular differentiation |
|
Micropapillary urothelial carcinomas |
|
Sarcomatoid urothelial carcinomas |
|
Nested variant of urothelial carcinomas |
|
Microcystic urothelial carcinomas |
|
Lymphoepithelioma-like urothelial carcinomas |
|
Plasmacytoid and lymphoma-like urothelial carcinomas |
|
Giant cell urothelial carcinomas |
|
Clear cell urothelial carcinomas |
|
Lipid cell variant of urothelial carcinomas |
|
Undifferentiated variant of urothelial carcinomas |
|
Urothelial carcinomas with trophoblastic differentiation |
|
Grading
According to the WHO grading criteria, there are two grades of transitional cell carcinoma based on the degree of cellular differentiation:
Grade | Description |
---|---|
Low grade |
|
High grade |
|
Associated Conditions
Following table illustrates the cancers that may be associated with transitional cell carcinoma of urinary tract:[8]
Association | Percentage of cases |
---|---|
Bladder cancer after the diagnosis of upper urinary tract transitional cell cancer |
20 - 50% |
Upper urinary tract transitional cell cancer after the diagnosis of bladder cancer |
0.74 - 4% |
Upper urinary tract transitional cell cancer after cystectomy |
2 - 9% |
References
- ↑ Rabbani F, Perrotti M, Russo P, Herr HW (January 2001). "Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance". J. Clin. Oncol. 19 (1): 94–100. doi:10.1200/JCO.2001.19.1.94. PMID 11134200.
- ↑ National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq#link/_359_toc Accessed on February 19, 2016
- ↑ 3.0 3.1 Cheng L, Cheville JC, Neumann RM, Bostwick DG (2000). "Flat intraepithelial lesions of the urinary bladder". Cancer. 88 (3): 625–31. PMID 10649257.
- ↑ Cheng L, Cheville JC, Neumann RM, Bostwick DG (1999). "Natural history of urothelial dysplasia of the bladder". Am J Surg Pathol. 23 (4): 443–7. PMID 10199474.
- ↑ 5.0 5.1 Pons F, Orsola A, Morote J, Bellmunt J (2011). "Variant forms of bladder cancer: basic considerations on treatment approaches". Curr Oncol Rep. 13 (3): 216–21. doi:10.1007/s11912-011-0161-4. PMID 21360040.
- ↑ McKenney JK, Amin MB, Young RH (2003). "Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases". Mod Pathol. 16 (7): 623–9. doi:10.1097/01.MP.0000073973.74228.1E. PMID 12861056.
- ↑ Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B; et al. (2013). "Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients". Urol Oncol. 31 (8): 1584–90. doi:10.1016/j.urolonc.2012.03.009. PMID 22520573.
- ↑ Kirkali, Ziya; Tuzel, Emre (2003). "Transitional cell carcinoma of the ureter and renal pelvis". Critical Reviews in Oncology/Hematology. 47 (2): 155–169. doi:10.1016/S1040-8428(03)00079-9. ISSN 1040-8428.